Etteplan's net sales in Q4 amounted to EUR 91.0m, below our estimates and below consensus (EUR 99.
Exel’s Q4 figures missed our and consensus estimates.
Pihlajalinna’s Q4 report was a clear disappointment in terms of profitability even after the guidanc...
Fellow Bank’s outlook for 2023 remains quite good and we expect continued growth and positive profit...
Marimekko delivered solid Q4 figures despite a challenging domestic market.
Redeye states that Chromogenics Q4 report was weak on topline with higher OPEX
Redeye updates its view on Starbreeze. The company continues to build a solid foundation around its ...
EQL Pharma redovisade återigen ett rekordkvartal för läkemedelsportföljen, drivet av nya produktlans...
Redeye comments on Tessin’s Q4 results, which came in lower than expected in terms of sales and prof...
Sales SEK 19.3m, -16% vs. ABGSCe SEK 22.8m EBITDA SEK -2.
Redeye leaves its comments on Stille’s Q4 2022 report.
Redeye provides an initial take on Enzymatica’s Q4 2022 report.
Redeye states AVTECH's Q4'22 report was in line with Redeye's estiamtes and in line with preliminary...
Germany sales above, EBIT in line Q4 numbers imply +9% to Germany sales 10x '24e EV/EBIT on pre-Q4 n...
Redeye concludes that Q4 came in somewhat below its estimates, but that sensor sales has now picked ...
Pathway to positive FCF significantly clearer More resilient to B2C volumes than we expected EV/ARR ...
Redeye comments on EG7’s Q4-results which was stronger than expected with EBITDA coming in 14% above...
Redeye provides an update in relation to SenzaGen’s H2 2022 report.
After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, st...
Redeye updates its view on Embracer post its Q3 report, which showed solid net sales but weaker prof...
